Cited 2 times in
Comparison of Clinical Outcomes for Glycopeptides and Beta-Lactams in Methicillin-Susceptible Staphylococcus Aureus Bloodstream Infections
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용찬 | - |
dc.contributor.author | 안진영 | - |
dc.date.accessioned | 2022-08-23T00:28:46Z | - |
dc.date.available | 2022-08-23T00:28:46Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/189452 | - |
dc.description.abstract | Purpose: This study aimed to provide compelling evidence of anti-staphylococcal beta-lactam use for methicillin-susceptible Staphylococcus aureus bloodstream infection (MSSA BSI). Materials and methods: We retrospectively collected data on patients with MSSA BSI who were admitted to two academic tertiary-care hospitals from 2010 to 2018. Only patients who received nafcillin, cefazolin, vancomycin, or teicoplanin as definitive therapy were included. The primary outcome was 28-day mortality. To perform unbiased comparisons between both treatments, we used inverse probability of treatment weighting (IPTW) analysis. Results: A total of 359 patients were divided into two groups based on the definitive therapy used: beta-lactams (n=203), including nafcillin or cefazolin; and glycopeptides (n=156), including vancomycin or teicoplanin. In the IPTW analysis, glycopeptides were associated with significantly increased odds of 28-day mortality (adjusted odds ratio, 3.37; 95% confidence interval, 1.71-6.61; p<0.001). The rate of primary outcome in prespecified subgroups was largely consistent with the main analysis. Conclusion: Definitive therapy with beta-lactams in patients with MSSA BSI was associated with lower 28-day mortality compared to definitive therapy with glycopeptides. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Anti-Bacterial Agents / therapeutic use | - |
dc.subject.MESH | Bacteremia* / drug therapy | - |
dc.subject.MESH | Cefazolin / adverse effects | - |
dc.subject.MESH | Glycopeptides / therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Methicillin / therapeutic use | - |
dc.subject.MESH | Nafcillin / adverse effects | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Sepsis* / complications | - |
dc.subject.MESH | Staphylococcal Infections* / complications | - |
dc.subject.MESH | Staphylococcal Infections* / drug therapy | - |
dc.subject.MESH | Staphylococcus aureus | - |
dc.subject.MESH | Teicoplanin / therapeutic use | - |
dc.subject.MESH | Vancomycin / therapeutic use | - |
dc.subject.MESH | beta-Lactams / therapeutic use | - |
dc.title | Comparison of Clinical Outcomes for Glycopeptides and Beta-Lactams in Methicillin-Susceptible Staphylococcus Aureus Bloodstream Infections | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yeon Ju La | - |
dc.contributor.googleauthor | Hye Rim Kim | - |
dc.contributor.googleauthor | Dong Hyun Oh | - |
dc.contributor.googleauthor | Jin Young Ahn | - |
dc.contributor.googleauthor | Yong Chan Kim | - |
dc.identifier.doi | 10.3349/ymj.2022.63.7.611 | - |
dc.contributor.localId | A00752 | - |
dc.contributor.localId | A02267 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 35748072 | - |
dc.subject.keyword | Methicillin-susceptible Staphylococcus aureus | - |
dc.subject.keyword | beta-lactams | - |
dc.subject.keyword | bloodstream infection | - |
dc.subject.keyword | glycopeptides | - |
dc.subject.keyword | inverse probability of treatment weighting | - |
dc.contributor.alternativeName | Kim, Yong Chan | - |
dc.contributor.affiliatedAuthor | 김용찬 | - |
dc.contributor.affiliatedAuthor | 안진영 | - |
dc.citation.volume | 63 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 611 | - |
dc.citation.endPage | 618 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.63(7) : 611-618, 2022-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.